The Cooper Companies (COO) Up 3.6% Since Last Earnings Report: Can It Continue?

The Cooper Companies (COO) reported mixed fiscal Q3 2025 results, with adjusted EPS of $1.10 beating consensus by 2.8% on operational improvements, but revenues of $1.06 billion missed estimates by 0.5% due to weakness in Clariti sales, particularly in Asia Pacific. Despite strong growth in MyDAY and MiSight lenses, the company subsequently lowered its full-year fiscal 2025 revenue guidance to $4,076-$4,096 million, while slightly adjusting its adjusted EPS outlook to $4.08-$4.12, leading to downward trending analyst estimates and a Zacks Rank #3 (Hold).

Analysis

The Cooper Companies (COO) reported mixed fiscal Q3 2025 results, characterized by strong bottom-line execution but a softening top-line outlook. The company delivered an adjusted EPS of $1.10, a 15% year-over-year increase that beat consensus estimates by 2.8%, driven by operational improvements and an approximate 100 basis point expansion in adjusted gross margin to 67%. However, revenues of $1.06 billion missed estimates by 0.5% and showed weak organic growth of only 2%. This top-line underperformance was primarily attributed to weakness in Clariti sales, which led to a 5% organic revenue decline in the Asia Pacific region. While pockets of strength were evident, including 23% growth in MiSight myopia lenses and a 20% rise in MyDAY multifocal lenses, these were not enough to offset the broader weakness. Critically, management lowered its full-year fiscal 2025 revenue guidance to a range of $4,076-$4,096 million, signaling that the headwinds are expected to persist. In a contrasting move, the adjusted EPS forecast was slightly raised to $4.08-$4.12, suggesting confidence in margin control despite lower sales expectations. This mixed picture is reflected in downward analyst estimate revisions and a Zacks Rank #3 (Hold), indicating a neutral near-term outlook.

Key Decisions for Investors

• Investors should weigh the company's strong operational performance and margin control, evidenced by the EPS beat and raised full-year guidance, against the risks posed by the lowered FY2025 revenue forecast.
• Closely monitor for a stabilization or recovery in Clariti sales and Asia Pacific organic growth in subsequent quarters, as these are the primary weak points driving the cautious outlook.
• Given the conflicting signals of a 'B' grade for value against a 'D' for momentum and a Zack's #3 (Hold) rating, a neutral stance may be prudent until there is clearer evidence of a re-acceleration in organic revenue growth.
• Acknowledge that continued double-digit growth in high-value products like MyDAY and MiSight lenses remains a key potential catalyst and a buffer against the softness observed in other parts of the business.